Table 6.
Summary of previous studies for the investigation of the efficacy of first-line eradication therapy for patients with penicillin allergies.
| First author [ref. no.] | Year | Method | VPZ-containing eradication regimen |
PPI-containing eradication regimen |
|||||
|---|---|---|---|---|---|---|---|---|---|
| Number | Regimen | Eradication rate | Number | Regimen | Eradication rate | ||||
| Ono (Ono et al., 2017) | 2017 | RST | ITT | 13 | VPZ: 20 mg bid MNZ: 250 mg bid CLR: 200 mg bid |
92.3% | 10 | LPZ: 30 mg bid or RPZ: 10 mg bid MNZ: 250 mg bid CLR: 200 mg bid |
50.0% |
| 14 | VPZ: 20 mg bid MNZ: 250 mg bid STFX: 100 mg bid |
92.9% | 20 | LPZ: 30 mg bid or RPZ: 10 mg bid MNZ: 250 mg bid STFX: 100 mg bid |
100% | ||||
| Sue (Sue et al., 2017b) | 2017 | RST | ITT | 20 | VPZ: 20 mg bid MNZ: 250 mg bid CLR: 200 or 400 mg bid |
100% | 30 | LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid MNZ: 250 mg bid CLR: 200 or 400 mg bid |
83.3% |
All paper to investigate efficacy of vonoprazan-containing eradication therapy for patients with penicillin allergies up until September 2018 were listed. bid, twice daily dosing; CLR, clarithromycin; EPZ, esomeprazole; ITT, intention to treat analysis; LPZ, lansoprazole; MNZ, metronidazole; PPI, proton pump inhibitor; RST, retrospective cohort trial; RPZ, rabeprazole; STFX, sitafloxacin; VPZ, vonoprazan.